NGM 313

Drug Profile

NGM 313

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antihyperglycaemics; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action Immunomodulators; Type 1 fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 01 Sep 2017 Phase-I clinical trials in Obesity in USA (Parenteral) (NCT03298464)
  • 01 Apr 2017 NGM Biopharmaceuticals completes a phase I trial in Obesity (In volunteers) in Australia (Parenteral) (NCT02708576)
  • 01 Feb 2016 Phase-I clinical trials in Obesity (In volunteers) in Australia (Parenteral) (NCT02708576)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top